Abstract
FDA in mid-December approved the marketing of fospropofol disodium injection, or Lusedra, as an agent for providing monitored anesthesia care sedation in adults undergoing diagnostic or therapeutic procedures. The drug is a water-soluble prodrug of the sedative–hypnotic agent propofol, which is
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
